Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.74 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.74 |
| ▸ | USP2 | O75604 | 1/20 | 0.74 |
| ▸ | TP53 | P04637 | 1/20 | 0.74 |
| ▸ | GFER | P55789 | 4/20 | 0.65 |
| ▸ | CASP6 | P55212 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | HTT | P42858 | 3/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13009470 | 0.94 | MAPT (0.67) | MAPTMAPK1HSD17B10USP2TP53 | |
| SCHEMBL2404063 | 0.85 | CA12 (0.69) | MAPTMAPK1HSD17B10USP2TP53 | |
| SCHEMBL14461239 | 0.84 | GFER (0.58) | MAPTMAPK1HSD17B10USP2TP53 | |
| SCHEMBL20178041 | 0.83 | HSD11B1 (0.57) | MAPTMAPK1HSD17B10USP2TP53 | |
| SCHEMBL19879705 | 0.83 | MAPK1 (0.55) | MAPTMAPK1HSD17B10USP2TP53 | |
| SCHEMBL23328249 | 0.82 | ALDH1A1 (0.56) | MAPTMAPK1HSD17B10USP2TP53 | |
| SCHEMBL762466 | 0.82 | MAPT (0.58) | MAPTMAPK1HSD17B10USP2TP53 | |
| SCHEMBL946765 | 0.81 | ALDH1A1 (0.57) | MAPTMAPK1HSD17B10USP2TP53 | |
| SCHEMBL12781689 | 0.81 | MAPT (0.67) | MAPTMAPK1HSD17B10USP2TP53 | |
| SCHEMBL82046 | 0.80 | GFER (0.71) | MAPTMAPK1HSD17B10GFERCASP6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230051842-A1 | HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER | ASANA BIOSCIENCES, LLC | 2023-02-16 | — | — | US | disclosed |
| US-20230027072-A1 | IMPROVED METHODS, KITS, COMPOSITIONS AND DOSING REGIMENS FOR THE USE OF HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 | ASANA BIOSCIENCES, LLC | 2023-01-26 | — | — | US | disclosed |
| US-20230009626-A1 | INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | ICHNOS SCIENCES S.A. (CH) | 2023-01-12 | — | — | US | disclosed |
| US-11365196-B2 | FGFR inhibitor and application thereof | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2022-06-21 | — | — | US | disclosed |
| US-20210130353-A1 | FGFR INHIBITOR AND APPLICATION THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2021-05-06 | — | — | US | disclosed |
| US-10766879-B2 | Pyrimidine derivatives as kinase inhibitors and their therapeutical applications | NANTBIOSCIENCE, INC. (US) | 2020-09-08 | — | — | US | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-10751332-B2 | Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer | ASANA BIOSCIENCES, LLC (US) | 2020-08-25 | — | — | US | disclosed |
| US-20200179356-A1 | HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER | ASANA BIOSCIENCES, LLC | 2020-06-11 | — | — | US | disclosed |
| US-10471051-B2 | Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer | ASANA BIOSCIENCES, LLC (US) | 2019-11-12 | — | — | US | disclosed |
| US-20090318407-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090318407-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090298823-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090298823-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | US | disclosed |
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | TARGEGEN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | TARGEGEN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | IMPACT BIOMEDICINES, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7528143-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318407-A1 | Inhibitors of protein kinases | SYK, BTK, JAK1 | MAPT 1178/4885MAPK1 163/4885HSD17B10 3229/4885 |
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, LTK | MAPT 4206/4885MAPK1 356/4885HSD17B10 4809/4885 |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | MAPT 3127/4885MAPK1 298/4885HSD17B10 4112/4885 |
| US-20230051842-A1 | HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER | KRAS, NRAS, RAF1 | MAPT 4699/4885MAPK1 7/4885HSD17B10 3637/4885 |
| US-11365196-B2 | FGFR inhibitor and application thereof | FGFR1, FGFR4, FGFR2 | MAPT 3243/4885MAPK1 788/4885HSD17B10 1443/4885 |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | MAPT 3127/4885MAPK1 298/4885HSD17B10 4112/4885 |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, JAK3 | MAPT 3127/4885MAPK1 298/4885HSD17B10 4112/4885 |
| US-10751332-B2 | Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer | KRAS, NRAS, RAF1 | MAPT 4699/4885MAPK1 7/4885HSD17B10 3637/4885 |
| US-10766879-B2 | Pyrimidine derivatives as kinase inhibitors and their therapeutical applications | DCK, TK1, DTYMK | MAPT 3434/4885MAPK1 402/4885HSD17B10 4141/4885 |
| US-20210130353-A1 | FGFR INHIBITOR AND APPLICATION THEREOF | FGFR1, FGFR4, FGFR2 | MAPT 3081/4885MAPK1 845/4885HSD17B10 1410/4885 |
| US-20230009626-A1 | INDOLINONE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS | MAP4K1, MAP4K2, MAP4K4 | MAPT 142/4885MAPK1 35/4885HSD17B10 2199/4885 |
| US-20090298823-A1 | Inhibitors of protein kinases | SYK, BTK, JAK2 | MAPT 4793/4885MAPK1 209/4885HSD17B10 2379/4885 |
| US-10471051-B2 | Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer | KRAS, NRAS, RAF1 | MAPT 4699/4885MAPK1 7/4885HSD17B10 3637/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | MAPT 438/4885MAPK1 280/4885HSD17B10 4376/4885 |
| US-20200179356-A1 | HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 AND THEIR USE IN THE TREATMENT OF CANCER | KRAS, NRAS, RAF1 | MAPT 4699/4885MAPK1 7/4885HSD17B10 3637/4885 |
| US-20230027072-A1 | IMPROVED METHODS, KITS, COMPOSITIONS AND DOSING REGIMENS FOR THE USE OF HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 | KRAS, NRAS, BRAF | MAPT 4372/4885MAPK1 8/4885HSD17B10 3727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.